Fibroma medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
====Gonadotropin-Releasing Hormone Analogues==== | ====Gonadotropin-Releasing Hormone Analogues==== | ||
Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause. Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin | *Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause. | ||
*Some of them are Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin | |||
*Effects of GnRH agonists are temporary, and re-growth has been reported in many cases of leiomyomas to their pretreatment sizes after stopping them. | |||
Revision as of 15:56, 24 June 2019
overview
Medical therapy depends on the type of fibroma.
Medical therapy
Uterine fibroma
At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.[1][2][3][4][5][6][7][8]
Gonadotropin-Releasing Hormone Analogues
- Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause.
- Some of them are Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin
- Effects of GnRH agonists are temporary, and re-growth has been reported in many cases of leiomyomas to their pretreatment sizes after stopping them.
- ↑ Sabry, Mohamed; Al-Hendy, Ayman (2012). "Medical Treatment of Uterine Leiomyoma". Reproductive Sciences. 19 (4): 339–353. doi:10.1177/1933719111432867. ISSN 1933-7191.
- ↑ Donnez, Jacques; Dolmans, Marie-Madeleine (2016). "Uterine fibroid management: from the present to the future". Human Reproduction Update. 22 (6): 665–686. doi:10.1093/humupd/dmw023. ISSN 1355-4786.
- ↑ Murji, Ally; Whitaker, Lucy; Chow, Tiffany L; Sobel, Mara L (2017). "Selective progesterone receptor modulators (SPRMs) for uterine fibroids". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010770.pub2. ISSN 1465-1858.
- ↑ Arena, Saverio; Zupi, Errico (2011). "Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option". Women's Health. 7 (2): 143–146. doi:10.2217/WHE.11.1. ISSN 1745-5065.
- ↑ De Leo, Vincenzo; Morgante, Giuseppe; La Marca, Antonio; Musacchio, Maria Concetta; Sorace, Massimo; Cavicchioli, Chiara; Petraglia, Felice (2002). "A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas". Drug Safety. 25 (11): 759–779. doi:10.2165/00002018-200225110-00002. ISSN 0114-5916.
- ↑ Sankaran, Srividhya; Manyonda, Isaac T. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology. 22 (4): 655–676. doi:10.1016/j.bpobgyn.2008.03.001. ISSN 1521-6934.
- ↑ Palomba, S. (2002). "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial". Human Reproduction. 17 (12): 3213–3219. doi:10.1093/humrep/17.12.3213. ISSN 1460-2350.
- ↑ Golan, A. (1996). "GnRH analogues in the treatment of uterine fibroids". Human Reproduction. 11 (suppl 3): 33–41. doi:10.1093/humrep/11.suppl_3.33. ISSN 0268-1161.